- Home
- HSTM vs ZYME Comparison
HSTM vs ZYME Comparison
Compare HSTM & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSTM
- ZYME
- Stock Information
- Founded
- HSTM 1990
- ZYME 2003
- Country
- HSTM United States
- ZYME United States
- Employees
- HSTM N/A
- ZYME N/A
- Industry
- HSTM Computer Software: Programming Data Processing
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- HSTM Technology
- ZYME Health Care
- Exchange
- HSTM Nasdaq
- ZYME Nasdaq
- Market Cap
- HSTM 846.5M
- ZYME 867.6M
- IPO Year
- HSTM 2000
- ZYME 2017
- Fundamental
- Price
- HSTM $27.10
- ZYME $13.30
- Analyst Decision
- HSTM Hold
- ZYME Buy
- Analyst Count
- HSTM 2
- ZYME 7
- Target Price
- HSTM $29.00
- ZYME $19.50
- AVG Volume (30 Days)
- HSTM 182.3K
- ZYME 494.5K
- Earning Date
- HSTM 07-21-2025
- ZYME 07-31-2025
- Dividend Yield
- HSTM 0.47%
- ZYME N/A
- EPS Growth
- HSTM 8.37
- ZYME N/A
- EPS
- HSTM 0.63
- ZYME N/A
- Revenue
- HSTM $292,371,000.00
- ZYME $93,384,000.00
- Revenue This Year
- HSTM $5.00
- ZYME $44.71
- Revenue Next Year
- HSTM $5.20
- ZYME $34.57
- P/E Ratio
- HSTM $42.34
- ZYME N/A
- Revenue Growth
- HSTM 3.36
- ZYME 85.05
- 52 Week Low
- HSTM $25.72
- ZYME $9.03
- 52 Week High
- HSTM $34.24
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- HSTM 43.17
- ZYME 61.39
- Support Level
- HSTM $26.60
- ZYME $12.75
- Resistance Level
- HSTM $27.60
- ZYME $13.80
- Average True Range (ATR)
- HSTM 0.50
- ZYME 0.42
- MACD
- HSTM 0.01
- ZYME 0.07
- Stochastic Oscillator
- HSTM 37.62
- ZYME 79.88
About HSTM HealthStream Inc.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.